Cerebral aneurysm future or investigational therapies

Investigational Therapies

Cerebral aneurysm Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cerebral aneurysm from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cerebral aneurysm future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cerebral aneurysm future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cerebral aneurysm future or investigational therapies
CDC on Cerebral aneurysm future or investigational therapies
Cerebral aneurysm future or investigational therapies in the news
Blogs on Cerebral aneurysm future or investigational therapies
Directions to Hospitals Treating Cerebral aneurysm
Risk calculators and risk factors for Cerebral aneurysm future or investigational therapies

In order to get cure from Cerebral Aneurysm, the most focusing should be reconstruction of vascular wall with normal endothelialization.

Currently, there are two main classes of pharmacology, used for this purpose.

Cell Therapies:

• Endothelial Progenitor cells (EPCs)
• Mesenchymal stem cells (MSCs)
• Vascular smooth muscle cells (VSMs)
• Fibroblasts

Drug Therapies:

• MCP-1 Inhibitors
• ACE inhibitors
• TNF-alpha Inhibitors

Future Perspectives:

The Subarachnoid Hemorrhage is consider as a major cause of Cerebral Aneurysm. The main goal for management of cerebral aneurysm is prevention of rupture or re-rupture.

The main management for CA is currently surgical procedures which only modify morphological aspects of aneurysm and cannot completely prevent from re-rupture.

Therefore, it is necessary to develop more effective and less risky treatments that are also fall in the line of cost-effectiveness.